<DOC>
	<DOCNO>NCT00002903</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness docetaxel treat patient recurrent refractory germ cell cancer .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Recurrent Refractory Germ Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether partial complete response achieve docetaxel ( TXT ) patient recurrent refractory disseminate germ cell cancer previously treat standard-dose chemotherapy . II . Assess probability actual response warrant evaluation therapeutic effectiveness TXT case partial complete tumor response achieve patient population . III . Characterize toxic effect TXT patient . OUTLINE : Patients receive intravenous docetaxel 1 hour every 3 week disease progression , unacceptable toxicity , least 3 course beyond documentation complete response . Patients may receive concurrent radiotherapy provide indicator lesion include irradiated field . Resection residual mature teratoma allow sooner 8 week therapy provide tumor marker normalize least 4 week . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm extragonadal gonadal germ cell tumor Seminoma nonseminoma eligible Recurrent refractory disease despite adequate firstline cisplatin carboplatinbased chemotherapy amenable surgery and/or curative radiotherapy Relapse diseasefree interval 1 year ineligible Measurable evaluable disease document progression within 2 month prior entry Elevated beta human chorionic gonadotropin alphafetoprotein consider evaluable evaluable lesion provide marker ( ) : Increased since end last treatment At least 10 time upper limit normal unless due tumor lysis Rising 3 successive occasion least 23 day apart If tumor marker available , cytology histology obtain No inadequately treat CNS metastases No pleural pericardial effusion and/or ascites PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute granulocyte count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.25 time normal AST/ALT great 3 time normal Alkaline phosphatase great 2.5 time normal Renal : Creatinine great 1.6 mg/dL Creatinine clearance least 60 mL/min creatinine borderline ( 1.11.6 mg/dL ) Other : No active infection No severe malnutrition No preexisting grade 2 bad neurotoxicity No preexisting edema No senility psychosis No expected difficulty followup include geographic consideration No malignancy except : Second testicular primary tumor Treated basocellular planocellular skin carcinoma Adequately treat carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior high dose chemotherapy without stem cell transplant At least 3 week since chemotherapy past WBC platelet nadir Endocrine therapy : Not specify Radiotherapy : Not amenable curative radiotherapy At least 3 week since radiotherapy recover Surgery : Not amenable surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
</DOC>